@tuts, bit confused mate, wonder if you can help......
As Aipac is progressive enrolment with treatment commencing on enrolment ......
So some have been treated much longer than the last to enrol...
OK...from the announcement....
• Progression Free Survival (PFS) Hazard Ratio improvement for eftilagimod alpha (efti) group versus
placebo at the 6-month landmark....
SO
How is the 6 month landmark determined when patients have been treated for varying lengths of time?
Also
that to me means some patients have presumably been treated for 2 years varying down to say 9 months (guess)
so theoretically there should be way more data available than has been released?
I note: midpoint of enrolment n113 in 2018...
My lack of medical knowledge is on show here but I think you"ll get where I'm coming from if you have the time...
Ann: Immutep AIPAC Ph2b Clinical Results & Update Webcast Slides, page-86
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
0.010(3.08%) |
Mkt cap ! $475.7M | |||
| Open | High | Low | Value | Volume |
| 32.5¢ | 33.5¢ | 32.0¢ | $584.2K | 1.787M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 311433 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 113721 | 6 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |